Pharmacy Revenue Integrity
CiiTA Logo White
Prepared for Ajanta Pharma USA Inc.

The greatest gross-to-net opportunities are often the ones you cannot see.

CiiTA helps pharmaceutical manufacturers identify, quantify, prevent, and recover hidden pharmacy-related revenue leakage.
30 minutes. No presentation. Confidential and collaborative, with nothing shared outside the conversation.

Your Estimated Exposure

$4.2M

Per Year
Estimated annual pharmacy-related revenue leakage at Ajanta Pharma USA Inc.

How we arrived at this

Derived from Ajanta's U.S. generic and specialty portfolio, weighted toward high-volume ophthalmic and dermatology lines where contract-pharmacy claim concentration and dispensing anomalies are most frequently observed. Approximately 1.4% of estimated U.S. net revenue.

~5%

of non-Medicaid sales are subject to a duplicate discount

1 to 3%

of total U.S. revenues are lost to pharmacy fraud

Millions

in revenue recovered by CiiTA solutions to date

The Gap: Why This Exposure Exists

Pharmaceutical manufacturers have built sophisticated capabilities around rebates, 340B, gross-to-net, and commercial operations. Yet today’s increasingly complex pharmacy ecosystem has created financial exposures that traditional transaction systems were never designed to detect.

The exposure is not a failure of your team. It is a gap in what the systems were built to see.

Diverse Collaboration

Where Hidden Revenue Leakage Often Begins

Many manufacturers start by evaluating commercial and Medicare 340B duplicate discounts, one of the most measurable sources of unnecessary rebate expense. Duplicate discounts are often just the first indicator of broader financial exposure. Organizations frequently uncover additional opportunities involving:

340B Duplicate Discounts

Where most engagements begin, and the most measurable.

Copay Card Fraud and Abuse

Program dollars redirected outside intended patient use.

Pharmacy Benefit Fraud

Claims activity that does not reconcile to legitimate dispensing.

Assistance Program Abuse

Assistance funds captured by parties they were not built for.

Pharmacy Billing Anomalies

Patterns that clear transaction systems but do not hold up.

Inventory Diversion

Product moving outside authorized channels.

Suspicious Dispensing Behavior

Outlier prescriber and pharmacy behavior at the account level.

Emerging Fraud Schemes

New patterns identified before they become industry-wide losses.

The Revenue Leakage Continuum

MOST MEASURABLE
Where most engagements begin

Duplicate
Discounts

Copay and
Assistance Abuse

Benefit &
Billing Fraud

Diversion &
Dispensing

Emerging
Schemes

LEAST VISIBLE
Where the largest exposure often sits
MOST MEASURABLE
Where most engagements begin
LEAST VISIBLE
Where the largest exposure often sits
Most manufacturers can see the left end of this continuum. The financial opportunity tends to concentrate toward the right, where transaction systems were never designed to look.

Wondering whether any of this applies to Ajanta Pharma USA Inc.?

That is the entire purpose of the first conversation.

Book A Call

Why CiiTA?

CiiTA occupies a unique position at the intersection of pharmaceutical finance, pharmacy operations, and revenue integrity. We focus exclusively on helping pharmaceutical manufacturers uncover hidden financial opportunities.

Proven Expertise

Deep pharmacy and manufacturer expertise, with gross-to-net and rebate experience behind every analysis.

Specialized Analytics

Financial analytics built for this problem specifically, translated into executive-level insight.

Collaborative Approach

Engagement alongside your internal teams, focused on practical and measurable outcomes.

What Executive Teams Gain

  • Greater financial visibility
  • Improved gross-to-net performance
  • Quantifiable revenue recovery opportunities
  • Earlier identification of emerging financial risks
  • Objective analysis that complements existing teams
  • A clearer understanding of pharmacy-related revenue integrity
chartResults That Matter Image

Sample Output

Highest-value asset for this page. A redacted screenshot of an actual CiiTA finding or Polaris output makes the offer concrete.

Illustration

Homepage-style line illustration. Suggested subject: executive reviewing results on a large display.

What the First Conversation Is Actually Like

Is this a sales pitch?

No. The first conversation is diagnostic. If there is no exposure worth pursuing, we will tell you that.

Do we have to share data to talk?

No data is required for the first conversation. Nothing is requested until you decide there's something worth measuring.

We already have teams on this.

Most manufacturers do. Our analysis complements internal teams rather than duplicating them, and looks where transaction systems were not designed to.

Start With A Conversation, Not A Sales Presentation

Our first discussion is confidential, collaborative, and focused on one question:

Could hidden pharmacy-related revenue leakage be affecting Ajanta Pharma USA Inc.?

If the answer is yes, we will help you understand where it exists, how it can be measured, and what opportunities may be available to improve financial performance.
Book A Call
Opens the booking calendar in a new tab
  • 30 minutes
  • Confidential
  • No data required to start
  • No obligation

Pharmacy revenue integrity for pharmaceutical manufacturers.
Identify. Quantify. Prevent. Recover.

Copyright 2026 ciitainc.com. Created by Left Right Labs.

ZoomInfo tracking snippet loads here